Richard Deming |

Dr. Richard L. Deming

Claim this profile

Mercy Medical Center - Des Moines

Expert in Breast Cancer
Expert in Cancer
178 reported clinical trials
242 drugs studied

About Richard L. Deming

Education:

  • Obtained MD from Creighton University School of Medicine in 1980.
  • Completed Residency in Radiation Oncology at the University of California, San Francisco.

Experience:

  • Internship at Naval Medical Center in 1981.
  • Served as Medical Director of Mercy Cancer Center and Chairman of the Oncology Service Line at Mercy Medical Center.
  • Founder and Chairman of Above + Beyond Cancer, a nonprofit organization.
  • Recipient of the Lane Adams Quality of Life Award and the St. George National Award.
  • Affiliated with Mercyone Des Moines Medical Center, boasting over 43 years of experience in Radiation Oncology.

Area of expertise

1Breast Cancer
Global Leader
Richard L. Deming has run 28 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 positive
Stage II
2Cancer
Global Leader
Richard L. Deming has run 27 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage III

Affiliated Hospitals

Image of trial facility.
Mercy Medical Center - Des Moines
Image of trial facility.
Mercy Cancer Center-West Lakes

Clinical Trials Richard L. Deming is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria

More about Richard L. Deming

Clinical Trial Related6 years of experience running clinical trials · Led 178 trials as a Principal Investigator · 75 Active Clinical Trials
Treatments Richard L. Deming has experience with
  • Nivolumab
  • Carboplatin
  • Cisplatin
  • Atezolizumab
  • Paclitaxel
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Richard L. Deming specialize in?
Is Richard L. Deming currently recruiting for clinical trials?
Are there any treatments that Richard L. Deming has studied deeply?
What is the best way to schedule an appointment with Richard L. Deming?
What is the office address of Richard L. Deming?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security